AU2012290127B2 - Inhibitors of influenza viruses replication - Google Patents

Inhibitors of influenza viruses replication Download PDF

Info

Publication number
AU2012290127B2
AU2012290127B2 AU2012290127A AU2012290127A AU2012290127B2 AU 2012290127 B2 AU2012290127 B2 AU 2012290127B2 AU 2012290127 A AU2012290127 A AU 2012290127A AU 2012290127 A AU2012290127 A AU 2012290127A AU 2012290127 B2 AU2012290127 B2 AU 2012290127B2
Authority
AU
Australia
Prior art keywords
fluoro
mmol
compound
minutes
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012290127A
Other languages
English (en)
Other versions
AU2012290127A1 (en
Inventor
Upul K. Bandarage
Randy S. Bethiel
Michael J. Boyd
Paul S. Charifson
Michael P. Clark
Ioana Davies
Hongbo Deng
John P. Duffy
Luc J. Farmer
Huai Gao
Wenxin Gu
Joseph M. Kennedy
Mark W. Ledeboer
Brian Ledford
Francois Maltais
Emanuele Perola
Tiansheng Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46650922&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012290127(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of AU2012290127A1 publication Critical patent/AU2012290127A1/en
Priority to AU2016228190A priority Critical patent/AU2016228190B2/en
Application granted granted Critical
Publication of AU2012290127B2 publication Critical patent/AU2012290127B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2012290127A 2011-08-01 2012-08-01 Inhibitors of influenza viruses replication Ceased AU2012290127B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016228190A AU2016228190B2 (en) 2011-08-01 2016-09-14 Inhibitors of influenza viruses replication

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161513793P 2011-08-01 2011-08-01
US61/513,793 2011-08-01
PCT/US2012/049097 WO2013019828A1 (en) 2011-08-01 2012-08-01 Inhibitors of influenza viruses replication

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016228190A Division AU2016228190B2 (en) 2011-08-01 2016-09-14 Inhibitors of influenza viruses replication

Publications (2)

Publication Number Publication Date
AU2012290127A1 AU2012290127A1 (en) 2013-05-02
AU2012290127B2 true AU2012290127B2 (en) 2016-10-27

Family

ID=46650922

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012290127A Ceased AU2012290127B2 (en) 2011-08-01 2012-08-01 Inhibitors of influenza viruses replication
AU2016228190A Ceased AU2016228190B2 (en) 2011-08-01 2016-09-14 Inhibitors of influenza viruses replication

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016228190A Ceased AU2016228190B2 (en) 2011-08-01 2016-09-14 Inhibitors of influenza viruses replication

Country Status (37)

Country Link
US (5) US9051319B2 (enExample)
EP (2) EP3147284B1 (enExample)
JP (3) JP5917692B2 (enExample)
KR (1) KR101967172B1 (enExample)
CN (3) CN103764654B (enExample)
AP (1) AP3867A (enExample)
AR (1) AR087418A1 (enExample)
AU (2) AU2012290127B2 (enExample)
CA (1) CA2844054C (enExample)
CL (1) CL2014000245A1 (enExample)
CO (1) CO6940412A2 (enExample)
CY (1) CY1118726T1 (enExample)
DK (1) DK2739623T3 (enExample)
EA (3) EA027210B1 (enExample)
EC (1) ECSP14013189A (enExample)
ES (2) ES2618919T3 (enExample)
GE (2) GEP201706698B (enExample)
HK (1) HK1223915A1 (enExample)
HR (1) HRP20170421T1 (enExample)
HU (1) HUE033752T2 (enExample)
IL (2) IL230618A (enExample)
IN (1) IN2014CN00562A (enExample)
LT (1) LT2739623T (enExample)
ME (1) ME02638B (enExample)
MX (1) MX339149B (enExample)
PE (1) PE20141209A1 (enExample)
PH (1) PH12014500257A1 (enExample)
PL (1) PL2739623T3 (enExample)
PT (1) PT2739623T (enExample)
RS (1) RS55858B1 (enExample)
SG (2) SG10201503835TA (enExample)
SI (1) SI2739623T1 (enExample)
TW (3) TWI619715B (enExample)
UA (2) UA118010C2 (enExample)
UY (1) UY34234A (enExample)
WO (1) WO2013019828A1 (enExample)
ZA (2) ZA201400604B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2380795T3 (es) * 2005-05-20 2012-05-18 Vertex Pharmaceuticals, Inc. Pirrolopiridinas útiles como inhibidores de proteínas quinasas
WO2009145814A2 (en) * 2008-03-10 2009-12-03 Vertex Pharmaceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
GEP20207129B (en) 2009-06-17 2020-07-10 Vertex Pharma Inhibitors of influenza viruses replication
EP2729465A2 (en) 2011-07-05 2014-05-14 Vertex Pharmaceuticals Incorporated Processes and intermediates for producing azaindoles
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
HRP20191525T1 (hr) 2013-11-13 2019-11-29 Vertex Pharma Inhibitori replikacije virusa influence
EP3421468B1 (en) 2013-11-13 2020-11-04 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
CN103922966B (zh) * 2014-04-14 2015-10-21 武汉大学 作为甲型流感病毒抑制剂的甲酰胺和异腈类化合物及其制备与应用
JP6577570B2 (ja) * 2014-08-08 2019-09-18 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー インフルエンザウイルス感染に使用するためのインドール類
DK3191489T3 (da) 2014-09-08 2021-03-29 Janssen Sciences Ireland Unlimited Co Pyrrolopyrimidiner til anvendelse ved influenzavirusinfektion
MA40773A (fr) * 2014-10-02 2017-08-08 Vertex Pharma Variants du virus influenza a
MA40772A (fr) * 2014-10-02 2017-08-08 Vertex Pharma Variants du virus de la grippe a
WO2016183120A1 (en) * 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
JP6704416B2 (ja) * 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
MA43298A (fr) 2015-11-27 2021-04-14 Janssen Sciences Ireland Unlimited Co Derives heterocycliques d'indole pour des infections par le virus de la influenza
EP3362451B1 (en) 2015-12-09 2023-04-12 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
EA201891576A1 (ru) * 2016-01-07 2018-11-30 Янссен Сайенсиз Айрлэнд Юси Функционализированные пентановые кислоты для применения при инфекциях, вызванных вирусом гриппа
KR20180100375A (ko) 2016-01-20 2018-09-10 얀센 사이언시즈 아일랜드 유씨 인플루엔자 바이러스 감염에서 사용하기 위한 아릴 치환 피리미딘
EP3492468B1 (en) * 2016-07-26 2022-02-23 Suzhou Longbiotech Pharmaceuticals Co., Ltd. Heterocyclic compound as jak inhibitor, and salts and therapeutic use thereof
WO2018033082A1 (en) 2016-08-16 2018-02-22 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
CN109641868B (zh) * 2016-08-30 2021-12-03 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
CN106478460B (zh) * 2016-09-28 2018-06-12 衢州学院 一种手性N-Boc-3-氨基-4-芳基-丁酸的合成方法
JP7034162B2 (ja) 2016-12-15 2022-03-11 サンシャイン・レイク・ファーマ・カンパニー・リミテッド インフルエンザウイルス複製の阻害剤及びその使用
WO2018127096A1 (en) * 2017-01-05 2018-07-12 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
CN110446711B (zh) 2017-03-02 2022-02-15 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
CN111511907A (zh) 2017-03-14 2020-08-07 加利福尼亚大学董事会 对病毒中免疫逃逸功能区域的全基因组鉴定
CN109384783A (zh) * 2017-08-09 2019-02-26 银杏树药业(苏州)有限公司 新型杂环化合物及其作为抗流感病毒抑制剂的医药用途
EP3829719B1 (en) 2018-07-27 2025-04-02 Cocrystal Pharma, Inc. Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication
CN112979647B (zh) * 2021-03-12 2022-05-20 浙江大学 含氮杂氨基酸的氮杂吲哚衍生物及制备和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010148197A1 (en) * 2009-06-17 2010-12-23 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4349552A (en) 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
PT85662B (pt) 1986-09-10 1990-06-29 Sandoz Sa Processo para a preparacao de derivados de aza-indol e de indolizina e de composicoes farmaceuticas que os contem
WO1990007926A1 (en) 1989-01-20 1990-07-26 Pfizer Inc. 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
FR2687402B1 (fr) 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
DE4304455A1 (de) 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
US6075037A (en) 1994-06-09 2000-06-13 Smithkline Beecham Corporation Endothelin receptor antagonists
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
CN1166636C (zh) 1999-01-07 2004-09-15 惠氏 用于治疗抑郁症的芳基哌嗪基-环己基吲哚衍生物
AU2494300A (en) 1999-01-07 2000-07-24 American Home Products Corporation 3,4-dihydro-2h-benzo(1,4)oxazine derivatives
US6313126B1 (en) 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
US6265403B1 (en) 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
AR028475A1 (es) 1999-04-22 2003-05-14 Wyeth Corp Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion.
US20030153560A1 (en) 1999-04-23 2003-08-14 Salituro Francesco G. Inhibitors of c-Jun N-terminal kinases (JNK)
EP1196167B1 (en) 1999-07-02 2006-04-19 Stuart A. Lipton Use of p38 MAPK inhibitors in the treatment of ophthalmic conditions
GB9919843D0 (en) 1999-08-20 1999-10-27 Smithkline Beecham Plc Novel compounds
DE19948417A1 (de) 1999-10-07 2001-04-19 Morphochem Ag Imidazol-Derivate und ihre Verwendung als Arzneimittel
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
CA2396693A1 (en) 1999-12-28 2001-07-05 Stephen T. Wrobleski Cytokine, especially tnf-alpha, inhibitors
WO2001060816A1 (en) 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
US7041277B2 (en) 2000-03-10 2006-05-09 Cadbury Adams Usa Llc Chewing gum and confectionery compositions with encapsulated stain removing agent compositions, and methods of making and using the same
CA2308994A1 (en) 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
AU2001284823B2 (en) 2000-08-14 2006-11-30 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazoles
MXPA03001962A (es) 2000-09-06 2004-03-26 Johnson & Johnson Metodo para tratar alergias utilizando pirazoles sustituidos.
CN1642973A (zh) 2000-09-06 2005-07-20 奥索-麦克尼尔药品公司 治疗变态反应的方法
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
DK1355904T3 (da) 2000-12-22 2007-10-15 Wyeth Corp Heterocyclindazol- og -azaindazolforbindelser som 5-hydroxytryptamin-6-ligander
JP4343534B2 (ja) 2001-03-02 2009-10-14 ゲーペーツェー バイオテック アクチェンゲゼルシャフト ３ハイブリッド・アッセイ・システム
WO2002072587A1 (en) 2001-03-14 2002-09-19 Wyeth Antidepressant azaheterocyclymethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
WO2002085896A1 (en) 2001-04-24 2002-10-31 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan
US6656950B2 (en) 2001-04-25 2003-12-02 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine
US6656947B2 (en) 2001-04-26 2003-12-02 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinazoline
ES2247327T3 (es) 2001-04-26 2006-03-01 Wyeth Derivados azaheterociclimetilicos antidepresivos (isrs) de 7,8-dihidro-3h-6,9-dioxa-1,3-diazaciclopenta(a) naftaleno.
US6593350B2 (en) 2001-04-26 2003-07-15 Wyeth Antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole
CA2445543A1 (en) 2001-04-26 2002-11-07 Hong Gao Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-¬1,4|-benzodioxans
EP1381614B1 (en) 2001-04-26 2006-08-02 Wyeth ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO¬2,3-f|QUINOXALINE
US6555560B2 (en) 2001-04-30 2003-04-29 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
EP1392700B1 (en) 2001-04-30 2004-09-29 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta(a)naphthalene
GB0111186D0 (en) 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
AU2002309769B2 (en) 2001-05-17 2008-04-17 Wyeth Processes for the synthesis of derivatives of 2,3-dihydro-1,4-dioxino-[2,3-f] quinoline
US6825190B2 (en) 2001-06-15 2004-11-30 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
US6903110B2 (en) 2001-07-25 2005-06-07 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene
CN100434079C (zh) 2001-08-14 2008-11-19 富山化学工业株式会社 吡嗪核苷酸/吡嗪核苷类似物及其医药用途
US20040236110A1 (en) 2001-09-26 2004-11-25 Ladouceur Gaetan H Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
WO2003031439A1 (en) 2001-10-05 2003-04-17 Wyeth Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1h-indole
US7361671B2 (en) 2001-11-15 2008-04-22 The Institute For Pharmaceutical Discovery, Inc. Substituted heteroarylalkanoic acids
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
US7304061B2 (en) 2002-04-26 2007-12-04 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of ERK2 and uses thereof
EP1501833B1 (en) 2002-04-26 2005-11-02 Pfizer Products Inc. N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
US7429609B2 (en) 2002-05-31 2008-09-30 Eisai R & D Management Co., Ltd. Pyrazole compound and medicinal composition containing the same
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
PT1532145E (pt) 2002-08-02 2007-01-31 Vertex Pharma Composiçoes de pirazole úteis como inibidores de gsk-3
AU2002368154A1 (en) 2002-08-08 2004-02-25 Ribapharm Inc. Improved synthesis for hydroxyalkylated heterocyclic bases
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
AU2003286711A1 (en) 2002-10-25 2004-05-13 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
MXPA05009068A (es) 2003-02-26 2005-10-19 Boehringer Ingelheim Pharma Dihidro-pteridinonas, metodo para la produccion y uso del mismo en la forma de farmacos.
JP4787150B2 (ja) 2003-03-06 2011-10-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｊｎｋ阻害剤
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
WO2004106298A1 (en) 2003-05-30 2004-12-09 Janssen Pharmaceutica N.V. Indole derivatives with an improved antipsychotic activity
WO2005000813A1 (en) 2003-05-30 2005-01-06 Imclone Systems Incorporated Heteroarylamino-phenylketone derivatives and their use as kinase inhibitors
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
CA2540828A1 (en) 2003-09-30 2005-04-14 Scios Inc. Heterocyclic amides and sulfonamides
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
CN1925855B (zh) 2003-12-19 2010-06-16 普莱希科公司 开发Ret调节剂的化合物和方法
US20070066641A1 (en) 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
GB0405055D0 (en) 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
CA2560454C (en) 2004-03-30 2013-05-21 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of jak and other protein kinases
EP1756108A2 (en) 2004-04-02 2007-02-28 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
ITMI20040874A1 (it) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
KR100476851B1 (ko) 2004-05-18 2005-03-17 (주)성신엔지니어링 중력식 섬유여과기
US20060058339A1 (en) 2004-06-17 2006-03-16 Ibrahim Prabha N Compounds modulating c-kit activity and uses therefor
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US20060122213A1 (en) 2004-06-30 2006-06-08 Francoise Pierard Azaindoles useful as inhibitors of protein kinases
WO2006015123A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP2439207A1 (en) 2004-10-04 2012-04-11 Millennium Pharmaceuticals, Inc. Lactam Compounds Useful as Protein Kinase Inhibitors
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
US7528138B2 (en) 2004-11-04 2009-05-05 Vertex Pharmaceuticals Incorporated Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
US20060122185A1 (en) 2004-11-22 2006-06-08 Jeremy Green Bicyclic inhibitors of Rho kinase
EP1828180A4 (en) 2004-12-08 2010-09-15 Glaxosmithkline Llc 1H-pyrrolo [2,3-BETA] PYRIDINE
WO2006065946A1 (en) 2004-12-16 2006-06-22 Vertex Pharmaceuticals Incorporated Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
US20060161001A1 (en) 2004-12-20 2006-07-20 Amgen Inc. Substituted heterocyclic compounds and methods of use
ES2320487T3 (es) 2005-02-03 2009-05-22 Vertex Pharmaceuticals, Inc. Pirrolopirimidinas utiles como inhibidores de proteina quinasas.
BRPI0610828A2 (pt) 2005-05-16 2010-07-27 Irm Llc compostos e composições como inibidores de proteìna quinase
ES2380795T3 (es) 2005-05-20 2012-05-18 Vertex Pharmaceuticals, Inc. Pirrolopiridinas útiles como inhibidores de proteínas quinasas
DK2395004T3 (en) 2005-06-22 2016-03-21 Plexxikon Inc Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
ES2401192T3 (es) 2005-09-30 2013-04-17 Vertex Pharmceuticals Incorporated Deazapurinas útiles como inhibidores de janus cinasas
CN101365700A (zh) 2005-11-15 2009-02-11 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氮杂吲唑
US20130096302A1 (en) 2005-11-22 2013-04-18 Hayley Binch Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
EP2537849A3 (en) 2006-01-17 2013-04-03 Vertex Pharmaceuticals, Inc. Azaindoles useful as inhibitors of janus kinases
KR20080095902A (ko) 2006-02-14 2008-10-29 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로서 유용한 디하이드로디아제핀
US7659283B2 (en) 2006-02-14 2010-02-09 Vertex Pharmaceuticals Incorporated Pyrrolo [3,2-C] pyridines useful as inhibitors of protein kinases
DE102006012617A1 (de) 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
RU2008143361A (ru) 2006-04-05 2010-05-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Деазапурины в качестве ингибиторов янус-киназ
CA2650196A1 (en) 2006-04-26 2007-11-01 Stewart James Baker Pyrimidine derivatives as pi3k inhibitors
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
WO2007146057A2 (en) 2006-06-09 2007-12-21 Wisconsin Alumni Research Foundation Screening method for modulators of viral transcription or replication
EP2038272B8 (en) 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
ES2657635T3 (es) 2006-08-08 2018-03-06 Chugai Seiyaku Kabushiki Kaisha Derivado de pirimidina como inhibidor de PI3K y uso del mismo
AU2007287428B2 (en) 2006-08-24 2011-08-11 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
US20130310418A1 (en) 2006-11-15 2013-11-21 Vertex Pharmaceuticals Incorporated Azaindazoles useful as inhibitors of kinases
CA2672612A1 (en) 2006-12-14 2008-06-26 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinase inhibitors
NZ577798A (en) 2006-12-21 2012-04-27 Vertex Pharma 5-cyano-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
TW200840581A (en) 2007-02-28 2008-10-16 Astrazeneca Ab Novel pyrimidine derivatives
EP2134709A1 (en) 2007-03-09 2009-12-23 Vertex Pharmaceuticals, Inc. Aminopyridines useful as inhibitors of protein kinases
NZ579485A (en) 2007-03-09 2012-02-24 Vertex Pharma Aminopyrimidines useful as inhibitors of protein kinases
MX2009009590A (es) 2007-03-09 2009-11-10 Vertex Pharma Aminopirimidinas utiles como inhibidores de proteinas cinasas.
PT2139892E (pt) 2007-03-22 2011-11-21 Takeda Pharmaceutical Pirimidodiazepinas substituídas úteis como inibidores da plk1
RU2339637C1 (ru) 2007-04-05 2008-11-27 Андрей Александрович Иващенко Блокаторы гистаминного рецептора для фармацевтических композиций, обладающих противоаллергическим и аутоиммунным действием
KR20090130105A (ko) 2007-04-05 2009-12-17 알라 캠, 엘엘씨 치환된 2,3,4,5-테트라히드로-1ｈ-피리도［4,3-ｂ］ 인돌, 그 제조방법 및 용도
AU2008282156B2 (en) 2007-07-31 2014-07-17 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
EP2190849B1 (en) 2007-08-15 2013-11-20 Vertex Pharmceuticals Incorporated 4-(9-(3,3-difluorocyclopentyl)-5,7,7-trimethyl-6-oxo-6,7,8,9-tetrahydro-5h-pyrimido[4,5-b[1,4]diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases
EP2610256B1 (en) 2007-09-28 2016-04-27 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
SG185289A1 (en) 2007-10-09 2012-11-29 European Molecular Biology Lab Embl Soluble fragments of influenza virus pb2 protein capable of binding rna-cap
KR20100093552A (ko) 2007-11-02 2010-08-25 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 ｃ-세타로서의 [1ｈ-피라졸로[3,4-ｂ]피리딘-4-일]-페닐 또는 -피리딘-2-일 유도체
PT2463282E (pt) 2007-11-05 2013-11-11 Novartis Ag Derivados de 4-benzilamino-1-carboxiacil-piperidina como inibidores de cetp úteis para o tratamento de doenças tais como hiperlipidemia ou arteriosclerose
RU2503676C2 (ru) 2008-02-25 2014-01-10 Ф.Хоффманн-Ля Рош Аг Пирролопиразиновые ингибиторы киназы
WO2009145814A2 (en) 2008-03-10 2009-12-03 Vertex Pharmaceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
WO2009125395A1 (en) 2008-04-09 2009-10-15 Technion Research & Development Foundation Ltd. Anti influenza antibodies and uses thereof
AU2009271663B2 (en) 2008-06-23 2014-04-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
EP2356122B1 (en) 2008-06-23 2019-03-20 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
JP2011529062A (ja) 2008-07-23 2011-12-01 バーテックス ファーマシューティカルズ インコーポレイテッド ピラゾロピリジンキナーゼ阻害剤
CA2731496A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
WO2010011768A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
BRPI0916295A2 (pt) 2008-07-23 2019-09-24 Vertex Pharma inibidores de pirazolopiridina tricíclica cinase
EP2427464A1 (en) 2009-05-06 2012-03-14 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
WO2011008915A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
JP5685895B2 (ja) * 2009-12-11 2015-03-18 株式会社リコー 画像処理装置、画像処理方法およびプログラム
ME02446B (me) 2010-04-07 2016-09-20 Vertex Pharma Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzoeve kiseline
KR20130094710A (ko) 2010-04-14 2013-08-26 어레이 바이오파마 인크. Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘
WO2011137022A1 (en) 2010-04-27 2011-11-03 Merck Sharp & Dohme Corp. Azaindoles as janus kinase inhibitors
WO2012083122A1 (en) 2010-12-16 2012-06-21 Vertex Pharmaceutical Incorporated Inhibitors of influenza viruses replication
CA2822059A1 (en) 2010-12-16 2012-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
CN103492381A (zh) 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
EP2729465A2 (en) 2011-07-05 2014-05-14 Vertex Pharmaceuticals Incorporated Processes and intermediates for producing azaindoles
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
AU2012336019A1 (en) 2011-11-07 2014-05-29 Vertex Pharmaceuticals Incorporated Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor
WO2013184985A1 (en) 2012-06-08 2013-12-12 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
KR102323515B1 (ko) 2013-09-12 2021-11-05 얀센 바이오파마, 인코퍼레이트. 아자-피리돈 화합물 및 이의 용도
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
EP3421468B1 (en) 2013-11-13 2020-11-04 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
MX2016006197A (es) 2013-11-13 2016-08-08 Vertex Pharma Formulaciones de compuestos de azaindol.
HRP20191525T1 (hr) 2013-11-13 2019-11-29 Vertex Pharma Inhibitori replikacije virusa influence
JP6577570B2 (ja) 2014-08-08 2019-09-18 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー インフルエンザウイルス感染に使用するためのインドール類
DK3191489T3 (da) 2014-09-08 2021-03-29 Janssen Sciences Ireland Unlimited Co Pyrrolopyrimidiner til anvendelse ved influenzavirusinfektion
MA40772A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus de la grippe a
MA40773A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus influenza a
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
MA43298A (fr) 2015-11-27 2021-04-14 Janssen Sciences Ireland Unlimited Co Derives heterocycliques d'indole pour des infections par le virus de la influenza
EA201891576A1 (ru) 2016-01-07 2018-11-30 Янссен Сайенсиз Айрлэнд Юси Функционализированные пентановые кислоты для применения при инфекциях, вызванных вирусом гриппа
KR20180100375A (ko) 2016-01-20 2018-09-10 얀센 사이언시즈 아일랜드 유씨 인플루엔자 바이러스 감염에서 사용하기 위한 아릴 치환 피리미딘
WO2017223231A1 (en) 2016-06-21 2017-12-28 Alios Biopharma, Inc. (s)-8-(benzhydryl )-6-isopropyl-3,5-dioxo- 5, 6,7,8,-tetrahydro-3h-pyrazino-[1,2-b]pyridazin-yl-isobutyrate antiviral agent for use in treating influenza
EP3609502A1 (en) 2017-04-12 2020-02-19 Vertex Pharmaceuticals Incorporated Combination therapies for treating influenza virus infection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010148197A1 (en) * 2009-06-17 2010-12-23 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication

Also Published As

Publication number Publication date
IL244597A0 (en) 2016-04-21
EA037372B1 (ru) 2021-03-22
WO2013019828A1 (en) 2013-02-07
UA122808C2 (uk) 2021-01-06
US20140094473A1 (en) 2014-04-03
TW201629061A (zh) 2016-08-16
SI2739623T1 (sl) 2017-07-31
JP5917692B2 (ja) 2016-05-18
NZ620086A (en) 2016-05-27
US9051319B2 (en) 2015-06-09
EP3147284A1 (en) 2017-03-29
US20150191468A1 (en) 2015-07-09
SG10201503835TA (en) 2015-06-29
TWI619715B (zh) 2018-04-01
CA2844054C (en) 2020-09-01
CN103764654B (zh) 2016-01-20
GEP201606531B (en) 2016-08-25
DK2739623T3 (en) 2017-04-24
US20180155342A1 (en) 2018-06-07
CA2844054A1 (en) 2013-02-07
CY1118726T1 (el) 2017-07-12
MX2014001067A (es) 2014-03-27
EA201500265A1 (ru) 2015-10-30
CN105481853A (zh) 2016-04-13
IL244597B (en) 2018-01-31
TW201313713A (zh) 2013-04-01
JP6259855B2 (ja) 2018-01-10
IL230618A0 (en) 2014-03-31
CN105503862A (zh) 2016-04-20
GEP201706698B (en) 2017-07-10
US20160355512A1 (en) 2016-12-08
IN2014CN00562A (enExample) 2015-04-03
NZ716783A (en) 2017-08-25
CN105503862B (zh) 2018-02-02
ES2618919T3 (es) 2017-06-22
HRP20170421T1 (hr) 2017-06-02
US20210040092A1 (en) 2021-02-11
HK1223915A1 (zh) 2017-08-11
EP2739623A1 (en) 2014-06-11
AU2016228190B2 (en) 2018-11-08
US10875855B2 (en) 2020-12-29
ZA201400604B (en) 2015-10-28
HUE033752T2 (en) 2017-12-28
PT2739623T (pt) 2017-04-03
JP2018062516A (ja) 2018-04-19
EA201490396A1 (ru) 2014-06-30
AU2012290127A1 (en) 2013-05-02
ES2763535T3 (es) 2020-05-29
AU2016228190A1 (en) 2016-10-27
EA201692506A2 (ru) 2017-06-30
TWI594997B (zh) 2017-08-11
SG10201503833SA (en) 2015-06-29
US9908878B2 (en) 2018-03-06
KR20140064812A (ko) 2014-05-28
CN103764654A (zh) 2014-04-30
UY34234A (es) 2013-02-28
TW201738241A (zh) 2017-11-01
ME02638B (me) 2017-06-20
AR087418A1 (es) 2014-03-19
US9394302B2 (en) 2016-07-19
CL2014000245A1 (es) 2014-08-18
UA118010C2 (uk) 2018-11-12
AP3867A (en) 2016-10-31
IL230618A (en) 2016-04-21
PE20141209A1 (es) 2014-09-19
ECSP14013189A (es) 2014-11-28
EP2739623B1 (en) 2017-01-11
JP2014521688A (ja) 2014-08-28
EP3147284B1 (en) 2019-09-25
EA201692506A3 (ru) 2017-10-31
CO6940412A2 (es) 2014-05-09
ZA201409246B (en) 2016-05-25
HK1194736A1 (zh) 2014-10-24
RS55858B1 (sr) 2017-08-31
KR101967172B1 (ko) 2019-04-09
PH12014500257A1 (en) 2017-04-07
PL2739623T3 (pl) 2017-07-31
JP2016121196A (ja) 2016-07-07
MX339149B (es) 2016-05-13
LT2739623T (lt) 2017-04-10
AP2014007402A0 (en) 2014-01-31
HK1223914A1 (zh) 2017-08-11
EA027210B1 (ru) 2017-06-30
TWI537268B (zh) 2016-06-11
EA023423B1 (ru) 2016-06-30

Similar Documents

Publication Publication Date Title
AU2012290127B2 (en) Inhibitors of influenza viruses replication
EP2651940A1 (en) Inhibitors of influenza viruses replication
WO2012083122A1 (en) Inhibitors of influenza viruses replication
EP2651941A1 (en) Inhibitors of influenza viruses replication
OA19823A (en) Inhibitors of influenza viruses replication.
NZ620086B2 (en) Inhibitors of influenza viruses replication
OA17028A (en) Inhibitors of influenza viruses replication.
NZ716783B2 (en) Inhibitors of influenza viruses replication
HK1223914B (en) Inhibitors of influenza viruses replication

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ CHARIFSON, PAUL S.; CLARK, MICHAEL P.; BANDARAGE, UPUL K.; BETHIEL, RANDY S.; BOYD, MICHAEL J.; DAVIES, IOANA; DENG, HONGBO; DUFFY, JOHN P.; FARMER, LUC J.; GAO, HUAI; GU, WENXIN; KENNEDY, JOSEPH M.; LEDFORD, BRIAN; LEDEBOER, MARK W.; MALTAIS, FRANCOIS; PEROLA, EMANUELE AND WANG, TIANSHENG

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired